BiotechTube

Aripiprazole + Risperidone/Quetiapine

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psychotic Disorders

Conditions

Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X

Trial Timeline

Nov 1, 2012 → Feb 1, 2016

NCT ID
NCT01739127

About Aripiprazole + Risperidone/Quetiapine

Aripiprazole + Risperidone/Quetiapine is a pre-clinical stage product being developed by Bristol Myers Squibb for Psychotic Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01739127. Target conditions include Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X.

What happened to similar drugs?

2 of 7 similar drugs in Psychotic Disorders were approved

Approved (2) Terminated (4) Active (2)
❌quetiapineAstraZenecaPhase 3
🔄QuetiapineAstraZenecaPhase 3
❌QuetiapineAstraZenecaPhase 3
✅Asenapine 5-20 mg daily + Placebo 1-4 tablets dailyMerckApproved
✅Ziprasidone HCL (oral)PfizerApproved
🔄AripiprazoleBristol Myers SquibbPhase 3
❌mifepristone + placeboCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01739127Pre-clinicalCompleted

Competing Products

14 competing products in Psychotic Disorders

See all competitors
ProductCompanyStageHype Score
Olanzapine, Amantadine + Olanzapine and placeboEli LillyPhase 1
29
risperidone IR and LAI formulationJohnson & JohnsonPhase 1
29
quetiapineAstraZenecaPhase 3
32
QuetiapineAstraZenecaPhase 3
40
QuetiapineAstraZenecaPhase 3
32
quetiapine + olanzapine + risperidoneAstraZenecaPre-clinical
26
Asenapine 5-20 mg daily + Placebo 1-4 tablets dailyMerckApproved
43
Ziprasidone HCL (oral)PfizerApproved
35
AripiprazoleBristol Myers SquibbPhase 3
40
mifepristone + placeboCorcept TherapeuticsPhase 3
29
Miricorlilant + Miricorlilant + PlaceboCorcept TherapeuticsPhase 2
32
Miricorilant + FluvoxamineCorcept TherapeuticsPhase 1
26
Miricorilant + PlaceboCorcept TherapeuticsPhase 2
32
Olanzapine + CORT118335 + PlaceboCorcept TherapeuticsPhase 1
26